Next Generation Sequencing versus Microarray – a Comparison Using a PI-3K Inhibitor

Epistem are pleased to announce their acquisition of the Illumina NextSeq 550 next generation sequencer. With tunable output and high data quality, it provides the flexible power you need for whole-genome, transcriptome, and targeted resequencing.

Gene expression profiles from plucked scalp hair to assess pharmacodynamic biomarkers following treatment of advanced solid tumors with a novel anti-cancer stem cell Wnt inhibitor

Wnt signaling pathway genes are crucial for cell fate determination and cell polarity during development. Ipafricept (OMP-54F28) is a first in class recombinant fusion protein producing a truncated decoy receptor that binds to a cystine-rich region of Wnt ligand and as a result it blocks the activation of the Wnt signaling. Here the authors described the results of a phase 1 first in-human clinical trial.

Epistem Bioinformatics Services

Epistem's pharmacogenomics division have provided biomarker discovery and validation studies with many sponsors. The bespoke nature of many of Epistem's services mean that bioinformatics analysis is always tailored to the nature of the study.

Plucked hair ex vivo model identifies novel Notch PD biomarker suitable for use in the clinic.

Epistem have validated plucked scalp hair as a robust ex vivo model allowing biomarker signature identification. Readouts in these models include expression profiling by microarray or RNA-Seq, and targeted assays by qPCR.